



SCIENTIFIC LETTER

The first year of experience with an extracorporeal resuscitation program for refractory in-hospital cardiac arrest



Resucitación extracorporea en la parada cardiorrespiratoria intrahospitalaria refractaria. experiencia del primer año de un programa de ECMO-RCP

Dear Editor,

Despite resuscitation strategies, outcomes remain poor in cardiac arrest, with an in-hospital cardiac arrest (IHCA) survival rate of 15–20% and severe neurological deficits in 10–20% of survivors.¹

ECPR (extracorporeal cardiopulmonary resuscitation) is the use of venoarterial ECMO in refractory cardiac arrest to maintain perfusion of vital organs. Recent guidelines^{2,3} recognize its potential benefit when compared to conventional cardiopulmonary resuscitation (CPR).

We report our experience during the first year of implementation of an ECPR program for IHCA.

We performed a retrospective analysis of prospectively collected data on all patients who underwent ECPR for refractory IHCA at Alvaro Cunqueiro University Hospital (Vigo, Spain) from November 2017 to November 2018.

Patients with refractory IHCA were eligible for ECPR if they had a witnessed arrest, CPR initiation within the first 5 min, and a presumably reversible etiology.

Exclusion criteria were age more than 75 years, unwitnessed arrests, asystole (except in case of witnessed arrests and evident aetiologies) or significant comorbidities.

The ICU-CPR team is alerted when a patient arrests in our center, and starts advanced CPR upon arrival. The ECPR code leader is responsible for evaluating if the patient is a potential candidate for ECPR, and if so, ECPR code is activated.

The intensivist or cardiothoracic surgeon starts percutaneous echo-guided femorofemoral venoarterial cannulation after 15–20 min of CPR. The Cardiohelp device (Maquet, Getinge, Germany) is used in all cases. An unfractionated heparin bolus (50–100 IU/kg) is administered during cannulation followed by an infusion.

After ECMO initiation, therapeutic temperature management is initiated (36 °C), and the patient is transferred to the catheterization laboratory or operation theater depending on the arrest etiology. A 7Fr backflow cannula is inserted to provide distal limb perfusion after completion of all interventions.

Patient data are collected as part of quality assurance protocols, and informed consent is obtained from a patient's relative. Data treatment was approved by the hospital ethics committee.

The primary outcome was functional favorable survival to hospital discharge, measured with cerebral performance category (CPC 1–2). Secondary outcomes include 1-month survival with a CPC score of 1–2, and complications.

Analysis was mainly descriptive. Baseline and follow-up categorical variables were summarized with frequencies and percentages and compared using the Fisher exact test. Baseline and follow-up continuous variables were summarized using the summary statistics *n*, median, and interquartile range (IQR). Statistical analyses were performed using SPSS (IBM, New York).

From November 2017 to November 2018, seven patients were included in the ECPR program (Table 1). Median age was 62 years (IQR 40–68 years). The main risk factors were arterial hypertension (71.4%) and a history of coronary artery disease (71.4%).

The most frequent cause of cardiac arrest was ST-elevation myocardial infarction (STEMI) in four cases (57.1%). Shockable rhythm was the initial rhythm in five (71.4%) patients.

All the cardiac arrests were witnessed and involved bystander CPR in less than 1 min. The median time from bystander CPR to advanced ICU CPR was 5 min (IQR 5–10 min). The median low-flow time was 55 min (IQR 36.25–62.5 min). The median low-flow time was lower in survivors (40 min; IQR 25–60 min) than in non-survivors (60 min; IQR 50–70 min), but the difference was not significant ($p=0.191$).

Table 2 shows the proceedings and outcome data. The median duration of ECMO support was 5 days (IQR 1–8 days). After commencement of ECMO, five patients (71.4%) underwent coronary angiography, three of whom underwent percutaneous coronary intervention.

Three (42.9%) patients survived to hospital discharge, 100% of survivors with CPC score of 1. Four patients (71.4%) survived 1 month after cardiac arrest with a CPC score of

Table 1 Demographics and arrest data.

Variable	Total	Patient1	Patient2	Patient3	Patient4	Patient5	Patient6	Patient7
<i>Demographics</i>								
Sex	Male 4 (57.1%)	Female	F	Male	M	F	M	M
<i>n</i> (%)								
Median age (years), (IQR)	62 (40–68)	23	41	70	68	62	57	67
SOFA score ^a	12 (11–17)	17	11	17	11	12	11	12
Median (IQR)								
<i>Risk factors N (%)</i>								
Smoker	1 (14.3)	–	–	+	–	–	–	–
Hypertension	5 (71.4)	–	–	+	+	+	+	+
Diabetes	0 (0)	–	–	–	–	–	–	–
History of ischemic heart disease	5 (71.4)	–	–	+	+	+	+	+
History of congestive cardiac failure	2 (28.6)	–	–	–	–	+	–	+
COPD	0 (0)	–	–	–	–	–	–	–
Chronic renal disease	1 (14.3)	–	–	–	–	–	–	+
<i>Arrest data</i>								
Initial rhythm	VT/VF 5 (71.4)	VT/VF	PEA	VT/VF	VT/VF	VT/VF	Asystole	VT/VF
<i>n</i> (%)								
Etiology		Fulminant myocarditis	Pulmonary embolism	STEMI	STEMI	STEMI	STEMI	Electrical storm
<i>n</i> (%)								
Arrest location		ICU	In transit to ICU	Cath lab	Cath lab	Cath lab	ICU	Ward
<i>n</i> (%)								
Time arrest to ECMO (min)	55 (36.25–62.5)	25	60	50	70	40	–	60
Median (IQR)								
Time arrest to advanced cpr (min)	5 (5–10)	0	5	10	10	10	5	5
Median (IQR)								
Time ICU arrival to ECMO (min)	35 (28.75–60)	25	60	40	60	30	–	30
Median (IQR)								
<i>Pre-ECMO Labs (Median, Iqr)</i>								
Worst Pre-ECMO Lactate Mmol/L ^b	13 (11–18)	20	10	16	18	13	13	11
Worst Pre-ECMO pH ^c	7.22 (7.07–7.4)	7.50	7.40	7.07	6.99	7.22	7.12	7.38
Pre-ECMO Creatinine (mg/dl)	1.8 (1.65–2)	1.8	0.2	2.04	1.7	1.65	13	1.9

M, Male; F, Female; COPD, Chronic Obstructive Pulmonary Disease; ECMO, Extracorporeal Membrane Oxygenation; IQR, Interquartile range.

^a SOFA (Sequential Organ Failure Assessment): worst SOFA score post-cardiac arrest. No difference was detected between survivors (12; IQR 11–17) and non-survivors (11.5; IQR 11–15.75); $p=0.81$.

^b Median worst pre-ECMO lactate: No significant difference ($p=0.95$) between survivors (13 mmol/L; IQR 10–20 mmol/L) and non-survivors (14.5 mmol/L; IQR 11.5–17.5 mmol/L).

^c Median worst pre-ECMO pH: survivors (7.37; IQR 7.22–7.50); non-survivors (7.14; IQR 6.99–7.38). No statistical significance ($p=0.112$).

Table 2 ECMO proceedings and outcome data.

Variable	Total	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
<i>Days on ECMO</i>	5 (1–8)	18	3	5	1	8	1	7
<i>Median (IQR)</i>								
<i>Days in ICU</i>	32 (12–53)	30	11	5	1	21	1	64
<i>Median (IQR)</i>								
<i>Survival N (%)</i>								
Survival to ICU discharge	3 (42.9)	+	+	-	-	+	-	-
1 month survival	4 (57.1)	+	+	-	-	+	-	+
Survival to hospital discharge	3 (42.9)	+	+	-	-	+	-	-
<i>Cerebral performance category (CPC) N (%)</i>								
CPC 1 (first month)	4 (57.1)	+	+	-	-	+	-	+
CPC 1 (hospital discharge)	3 (42.9)	+	+	-	-	+	-	-
<i>Complications N (%)</i>								
Insufficient ECMO flow ^a	3 (42.8)	-	-	+	+	-	+	-
LV distension	1 (14.3)	+	-	-	-	-	-	-
Cannulation site bleeding (severity according to BARC) ^b	1 (14.2)	-	+(3)	-	-	-	-	-
Intracranial complications	0 (0)	-	-	-	-	-	-	-
Limb ischemia	0 (0)	-	-	-	-	-	-	-
AKI (R:Recovery)	3 (42.8)	+(R)	+(R)	+	-	-	-	-
<i>Cause of death</i>								
		-	-	MOF(WLS)	No flow	-	No flow	WLS

ECMO, Extracorporeal membrane oxygenation; ICU, Intensive Care Unit; IQR, Interquartile range; CPC, Cerebral Performance category; CPR, cardiopulmonary resuscitation; LV, left ventricle; AKI, Acute kidney injury; MOF, Multiorgan Failure; WLS, Withdrawal of life support.

^a Insufficient ECMO flow: An ECMO flow > 1 L/min could not be achieved in patients 3, 4 and 6 after ECMO initiation. Patients 3 and 4 suffered sternal fracture and mediastinal hematoma secondary to mechanical chest compressions, leading to insufficient ECMO flow (patient 4 died immediately. Flow could be restored in patient 3 after sternotomy, but he developed multiorgan failure). Patient 6 died immediately after ECMO initiation. Necropsy did not show vessel, cardiac or thoracic injury.

^b BARC (Bleeding Academic Research Consortium): bleeding severity according to BARC classification is shown in brackets.

1 (patient 7 was finally withdrawn from life support after being considered not suitable for further procedures).

The main cause of death was an impossibility to achieve an adequate ECMO flow shortly after cannulation in 3 patients. No patients suffered intracranial complications or limb ischemia.

ECPR has emerged as a promising technique in refractory cardiac arrest. The rate of survival with favorable neurological outcomes after 16 min of conventional CPR is reported to be less than 2%.⁴

Nevertheless, ECMO maintains organ perfusion, which could halt the accumulation of ischemic injury providing time to reverse the underlying etiology. A neurologically favorable survival has been observed in ECPR after prolonged CPR (25% survival with >50 min of CPR and 19% with more than 60 min) compared to 0% survival after 40 min of conventional CPR.⁵

Although there is a lack of definite evidence, several recent studies^{6,7} and meta-analysis⁸ have shown promising results with ECPR compared to CPR, with neurologically favorable survival rates greater than 30%.

There are few reports of ECPR programs in Spain.⁹ Establishing an ECPR program requires thorough training, organization and protocolization. The key of a successful program is to reduce barriers to achieve quick deployment of ECMO.¹⁰ Three factors are paramount. First, rapid and individualized decision-making, with an ECPR leader in charge of activating ECPR code. Ideally, the CPR leader and ECPR leader should be different to optimize both procedures. An ECMO specialist is available 24 h in our ICU, assuming the ultimate decision about activating ECPR code.

Second, a rapid team deployment is crucial to reduce no-flow and low-flow time, as they have been described as critical factors for survival. Quality practices should analyze time intervals to work specifically in each one to avoid unnecessary delays.

Finally, cannulation is subject to potentially devastating complications, especially if performed in an unfamiliar environment. In our case, all patients are transferred to the ICU for cannulation, except if they arrest in the catheterization laboratory.

Our experience suggests that an ECPR program is feasible and increase survival in selected patients. Given the high complexity of these patients, an ICU-based multidisciplinary approach may offer a better advantage in terms of covering the range of arrest aetiologies and the best synchronization of CPR and ECPR teams.

Our study has limitations. First, it is a single-center study. Furthermore, the small sample size and its retrospective nature make it underpowered to reach definite conclusions.

Conflict of interest

None.

References

1. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. *Circulation*. 2004;110:522–7.
2. Perkins GD, Olasveengen TM, Maconochie I, Soar J, Wyllie J, Greif R, et al. European resuscitation council guidelines for resuscitation: 2017 update. *Resuscitation*. 2018;123:43–50.
3. Fernández-Mondéjar E, Fuset-Cabanesc MP, Grau-Carmona T, López-Sánchez M, Peñuelas O, Pérez-Vela JL, et al. Empleo de ECMO en UCI. Recomendaciones de la sociedad española de medicina intensiva crítica y unidades coronarias. *Med Intensiva*. 2019;43:108–20.
4. Reynolds JC, Frisch A, Rittenberger JC, Callaway CW. Duration of resuscitation efforts and functional outcome after out-of-hospital cardiac arrest: when should we change to novel therapies? *Circulation*. 2013;128:2488–94.
5. Bartos JA, Grunau B, Carlson C, Duval S, Ripeckyj A, Kalra R, et al. Improved survival with extracorporeal cardiopulmonary resuscitation despite progressive metabolic derangement associated with prolonged resuscitation. *Circulation*. 2020, <http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042173>.
6. Lunz D, Calabro L, Belliato M, Contri E, Broman LM, Scandroglio AM et al. Extracorporeal membrane oxygenation for refractory cardiac arrest: a retrospective multicenter study. *Intensive Care Med*. doi:10.1007/s00134-020-05926-6.
7. Dennis M, Buscher H, Gattas D, Burns B, Habig K, Bannon P, et al. Prospective observational study of mechanical cardiopulmonary resuscitation, extracorporeal membrane oxygenation and early reperfusion for refractory cardiac arrest in Sydney: the 2CHEER study. *Crit Care Resus*. 2020;22:26–34.
8. Twohig CJ, Singer B, Grier G, Finney S. A systematic literature review and meta-analysis of the effectiveness of extracorporeal-CPR versus conventional-CPR for adult patients in cardiac arrest. *J Intensive Care Soc*. 2019;20:347–57.
9. García-Carreño J, Sousa-Casasnovas I, Devesa-Cordero C, Gutiérrez-Ibañes E, Fernández-Avilés F, Martínez-Sellés M. Reanimación cardiopulmonar con ECMO percutáneo en parada cardiaca refractaria hospitalaria: experiencia de un centro. doi:10.1016/j.recesp.2019.02.007.
10. Laussen P, C Guerguerian AM. Establishing and sustaining an ECPR program. *Front Pediatr*. 2018;6:152.

J.I. Chico-Carballas^{a,*}, A. Touceda-Bravo^a, S. Freita-Ramos^a, D. Mosquera-Rodríguez^a, V. Gómez-Casal^a, M. Piñon-Esteban^b

^a Hospital Álvaro Cunqueiro, Critical Care Department, Av/ clara campoamor 341, Vigo (pontevedra) 36312, Spain

^b Hospital Álvaro Cunqueiro, Cardiothoracic Surgery Department, Av/ clara campoamor 341, Vigo (pontevedra) 36312, Spain

* Corresponding author.

E-mail address: ji_chico@hotmail.com

(J.I. Chico-Carballas).